A new bipartisan bill, MOTAA 2.0, aims to let specially trained practitioners prescribe methadone for opioid use disorder (OUD) at community pharmacies — a major shift from the current system that largely limits access to specialized opioid treatment programs (OTPs). The American Society of Addiction Medicine (ASAM) is backing the move, citing research that methadone cuts all-cause mortality by more than half. Built-in safeguards aim to prevent misuse while broadening patient reach.
The American Society of Addiction Medicine (ASAM) is throwing its weight behind the Modernizing Opioid Treatment Access Act 2.0 of 2026 (MOTAA 2.0), a bipartisan bill introduced by Senators Ed Markey and Rand Paul. If passed, the legislation would allow highly trained addiction specialist physicians to prescribe methadone for opioid use disorder (OUD) directly at community pharmacies — a significant departure from the current federal framework that largely restricts methadone dispensing to specialized opioid treatment programs (OTPs).
The push comes amid persistent access gaps: roughly 8% of U.S. counties lack an OTP entirely, and even where programs exist, travel distance remains a real barrier for patients who risk missing critical doses. For patients dealing with high-potency synthetic opioids like fentanyl, full opioid agonist therapy like methadone can be lifesaving.
Key Takeaways:
Why it matters: Methadone reduces fatal overdose risk and cuts all-cause mortality by more than half, yet access remains tightly restricted. MOTAA 2.0 could be a turning point in integrating addiction treatment into mainstream healthcare.
